xCELLigence Cardio ECR – Agilent technologies

Monitor Cardiomyocyte beating and electric activity in real time

The new xCELLigence RTCA CardioECR system combines impedance and Multi Electrode Array (MEA) technology with a pacing function. RTCA CardioECR is the first platform to allow simultaneous real-time measurement of cardiomyocyte contractility by impedance, and electric activity by field potential measurement. The system is designed to be placed in a standard tissue culture incubator with physiological temperature, CO2 level and humidity, allowing better controlled assays with both short-term and long-term measurements in real-time.
 
With the added MEA capabilities and pacing stimuli, the new CardioECR System allows for a deeper assessment of mechanism of toxicity. Field potential recording provided by MEA electrodes is a measure of the integrated ion channel activity that may be impacted by the tested compound, whereas the pacing function allows for controlling the rate of contractility for a more controlled assay. Furthermore, this combined dual readout system also provides a longer-term measurement of cardiomyocyte viability which can potentially identify those compounds causing longer-term structural damage to cardiomyocytes.
 
The RTCA CardioECR Instrument is composed of four main components: 

• RTCA CardioECR Station
• RTCA CardioECR Analyzer
• RTCA CardioECR Control Unit
• E-Plate CardioECR 48

RTCA CardioECR Instrument Highlights:

• Real-time: short (hrs) and long-term (days) assay
• High throughput: conduct MEA and impedance assay simultaneously on a 48-well format
• Pacing function: 100% pacing success rate across the plate
• Tri-mode:
  • RTCA mode – determination of cell growth status over the assay time
  • Cardio mode – observation of cardiac beating activity over the assay time
  • CardioECR mode -simultaneous  recording of  cardio beating activity and electric activity (field potential)over the assay time

More info at: https://www.aceabio.com/products/rtca-cardioecr/